Program
SRX246
Its studies are mostly in Fragile X Syndrome · Disruptive, Impulse Control, and Conduct Disorders · Huntington Disease · Stress Disorders, Post-Traumatic · Anxiety Disorders, led by Azevan Pharmaceuticals.
Furthest: phase 2, since Feb 3, 20147 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Azevan Pharmaceuticals | 71 open or running | phase 2since Feb 3, 2014 | May 27, 2009 | Dec 2027phase 2 · NCT07328529 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2009First study: phase 1 study in HealthyFirst studyNCT00910455 · 49 enrolled · United States
- Mar 15, 2010Phase 1 study in HealthyNCT01088932 · 24 enrolled · United States
- Feb 3, 2014Phase 2 study in Disruptive, Impulse Control, and Conduct DisordersNCT02055638 · 97 enrolled · United States
- Jul 22, 2015Phase 2 study in Huntington DiseaseNCT02507284 · 106 enrolled · United States
- Mar 29, 2016Phase 2 study in Stress Disorders, Post-TraumaticNCT02733614 · 33 enrolled · United States
- Sep 29, 2016Phase 1 study in Anxiety DisordersNCT02922166 · 36 enrolled · United States
- Jan 7, 2026Phase 2 study in Fragile X SyndromeNCT07328529 · 80 planned · United States
Ahead
- Dec 2027Primary completion: phase 2 study in Fragile X SyndromeNCT07328529
TargetBeta
AVPR1A →read by rule
“Vasopressin V1a receptor antagonist”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07328529Fragile X Syndrome · United States | 2 | Not yet recruiting | Dec 2027 | 80 |
| NCT02922166Anxiety Disorders · United States | 1 | UNKNOWN | May 10, 2019 | 36 |
| NCT02733614Stress Disorders, Post-Traumatic · United States | 2 | Terminated | Oct 2020 | 33 |
| NCT02507284Huntington Disease · United States | 2 | Completed | Sep 10, 2018 | 106 |
| NCT02055638Disruptive, Impulse Control, and Conduct Disorders · United States | 2 | Completed | May 2016 | 97 |
| NCT01088932Healthy · United States | 1 | Completed | Jun 2010 | 24 |
| NCT00910455Healthy · United States | 1 | Completed | Sep 2009 | 49 |
How it is read
Names in the registry
- “SRX246”, 7 entries
Conditions, from the studies’ own filings
- Fragile X Syndrome, 1 study
- Disruptive, Impulse Control, and Conduct Disorders, 1 study
- Huntington Disease, 1 study
- Stress Disorders, Post-Traumatic, 1 study
- Anxiety Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.